EMA Authorised: Caprelsa (vandetanib) — Esteve Pharmaceuticals, S.A.

View source ↗

Summary

Caprelsa (vandetanib) has been authorised by the EMA for thyroid neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Neoplasms

Drugs mentioned

• Caprelsa (vandetanib)

Snippet

Status: Authorised. Therapeutic area: Thyroid Neoplasms. MAH: Esteve Pharmaceuticals, S.A.. Decision date: 03/08/2026